Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 6/20 | 1.00 |
| ▸ | FYN | P06241 | 5/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721915 | 1.00 | MAP3K11 (1.00) | MAP3K11FYNCHEK2CHEK1RAF1 | |
| SCHEMBL722935 | 0.90 | MAP3K11 (0.81) | MAP3K11FYNCHEK2CHEK1RAF1 | |
| SCHEMBL722936 | 0.90 | MAP3K11 (0.81) | MAP3K11FYNCHEK2CHEK1RAF1 | |
| SCHEMBL721314 | 0.86 | MAP3K11 (0.81) | MAP3K11FYNRAF1NTRK1CCNA2 | |
| SCHEMBL721315 | 0.86 | MAP3K11 (0.81) | MAP3K11FYNRAF1NTRK1CCNA2 | |
| SCHEMBL720206 | 0.85 | MAP3K11 (0.80) | MAP3K11FYNCHEK1RAF1NTRK1 | |
| SCHEMBL720205 | 0.85 | MAP3K11 (0.80) | MAP3K11FYNCHEK1RAF1NTRK1 | |
| SCHEMBL720207 | 0.85 | MAP3K11 (0.80) | MAP3K11FYNCHEK1RAF1NTRK1 | |
| SCHEMBL723137 | 0.83 | MAP3K11 (0.72) | MAP3K11FYNRAF1NTRK1CCNA2 | |
| SCHEMBL723138 | 0.83 | MAP3K11 (0.72) | MAP3K11FYNRAF1NTRK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-9181247-B2 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2379561-B1 | MLK INHIBITORS AND METHODS OF USE | UNIV ROCHESTER (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| EP-2925319-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | University Of Rochester (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20150105401-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER (US) | 2015-04-16 | — | — | US | disclosed |
| US-8877772-B2 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors | UNIVERSITY OF ROCHESTER (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014085795-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885FYN 567/4885CHEK2 101/4885 |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | MAP3K11 25/4885FYN 465/4885CHEK2 382/4885 |
| US-20150105401-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885FYN 567/4885CHEK2 101/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | MAP3K11 45/4885FYN 394/4885CHEK2 104/4885 |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885FYN 567/4885CHEK2 101/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885FYN 567/4885CHEK2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.